Skip to main content
CHA Vaccine Research Institute logo

CHA Vaccine Research Institute — Investor Relations & Filings

Ticker · 261780 ISIN · KR7261780001 KO Manufacturing
Open in API
Filings indexed 139 across all filing types
Latest filing 2024-09-04 Capital/Financing Update
Country KR South Korea
Listing KO 261780

About CHA Vaccine Research Institute

http://en.chavaccine.com/

CHA Vaccine Research Institute is a research-oriented biotechnology company focused on developing vaccines and immunotherapeutics for the prevention and treatment of infectious diseases. The company's core strategy involves leveraging proprietary adjuvant platforms, such as L-pampo and L-pampo, which are based on Toll-like receptor (TLR) ligands, to enhance vaccine efficacy. Its development pipeline includes a third-generation prophylactic vaccine and a therapeutic vaccine for Hepatitis B (HBV), a recombinant vaccine for herpes zoster (shingles), and an improved influenza vaccine. In addition to its vaccine portfolio, the institute is developing immunotherapeutic proteins like recombinant Mannose-Binding Lectin (MBL) for broad-spectrum pathogen suppression.

Recent filings

Filing Released Lang Actions
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities (Financial Services Commission/Korea Exchange) regarding the issuance of convertible bonds (전환사채권 발행결정). This type of filing is a standard regulatory disclosure for capital raising activities in the Korean market, which falls under the 'Capital/Financing Update' category.
2024-09-04 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 1% confidence The document is a short announcement (974 characters) regarding the scheduling and logistics of an upcoming Investor Relations (IR) presentation/meeting. It provides the date, time, location (online), and purpose of the event, and mentions where the materials will be available. Since it is an announcement of an event rather than the presentation slides themselves, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Report Publication Announcement (RPA) or general regulatory filing. Given the specific nature of announcing an IR event, RPA is the most accurate fit.
2024-08-26 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-Annual Report) for the company '차백신연구소' (CHA Vaccine Research Institute) covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business descriptions, and management reports, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-13 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'CHA Vaccine Research Institute' (주식회사 차백신연구소) covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial and business information, including management discussion, capital changes, and business operations, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a mandatory disclosure of insider share transactions, specifically reporting changes in share ownership by a company executive (Cho Jungki). In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS).
2024-04-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of a specific individual (Ko Jung Jae, an executive at Cha Vaccine Institute). This is a standard regulatory filing for insider trading/director dealings, which corresponds to the 'Director's Dealing' category.
2024-04-02 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.